Prospective Multicenter, Multinational Study to Evaluate the Safety and Efficacy of Concurrent Collagenase Clostridium Histolyticum Injections to Concurrently Treat 2 Dupuytren Contractures in the Same Hand

In early 2010, collagenase clostridium histolyticum (CCH) injection(s), 0.58 mg, was approved by the US Food and Drug Administration for the treatment of Dupuytren contracture in adults with a palpable cord. Following injection cord rupture 24 h later was accomplished by finger manipulation in extension. Subsequently, regulatory agencies around the world also approved this treatment method as safe and effective. This study was conducted to evaluate the safety and efficacy of concurrent administration of two collagenase clostridium histolyticum (CCH) injections (each 0.58 mg) into cords in the same hand to concurrently treat two joints with Dupuytren fixed flexion contractures (FFC) with palpable cords.